Necrostatin: a Potentially Novel Cardioprotective Agent?
Overview
Pharmacology
Authors
Affiliations
Background: Necrostatin-1 (Nec-1), a small tryptophan-based molecule, was recently reported to protect the cerebral cortex against ischemia-reperfusion (I/R) injury. We investigated the actions of Nec-1 and its so-called inactive analog, Nec-1i, in the setting of myocardial I/R injury.
Materials And Methods: The actions of Nec-1 and Nec-1i were examined in cultured C2C12 and H9c2 myocytes, cardiomyocytes isolated from male Sprague-Dawley rats, Langendorff isolated perfused C57Bl/6J mouse hearts and an in vivo open-chest C57Bl/6J mouse heart model.
Results: Nec-1 at 30 microM and 100 microM (but not 100 microM Nec-1i) reduced peroxide-induced cell death in C2C12 cells from 51.2 +/- 1.1% (control) to 26.3 +/- 2.9% (p < 0.01 vs control) and 17.8 +/- 0.9% (p < 0.001), respectively. With H9c2 cells cell death was also reduced from 73.0 +/- 0.4% (control) to 56.7 +/- 0% (30 microM Nec-1, p < 0.05) and 45.4 +/- 3.3% (100 microM Nec-1, p < 0.01). In the isolated perfused heart Nec-1 (30 microM) reduced infarct size (calculated as a percentage of the risk area) from 48.0 +/- 2.0% (control) to 32.1 +/- 5.4% (p < 0.05). Nec-1i (30 microM) also reduced infarct size (32.9 +/- 5.1%, p < 0.05). In anesthetized C57Bl/6J mice Nec-1 (1.65 mg/kg), given intraperitoneally to coincide with reperfusion following left anterior descending artery ligation (30 min), also reduced infarct size from 45.3 +/- 5.1% (control) to 26.6 +/- 4.0% (p < 0.05), whilst Nec-1i (1.74 mg/kg) was ineffective (37.8 +/- 6.0%). Stimulus-induced opening of the mitochondrial permeability transition pore (MPTP) in rat cardiomyocytes, as reflected by the time until mitochondrial depolarisation, was unaffected by Nec-1 or Nec-1i at 30 muM but increased at 100 muM i.e. 91% (p < 0.05 vs control) and 152% (p < 0.001) for Nec-1 and Nec-1i, respectively.
Conclusion: This is the first study to demonstrate that necrostatins inhibit myocardial cell death and reduce infarct size, possibly via a mechanism independent of the MPTP.
Reperfused Myocardial Infarction: The Road to CCS Classification of Acute MI and Beyond.
Dharmakumar R, Kloner R, Fishbein M, Heusch G, Vora K, Gropler R JACC Adv. 2025; 4(2):101528.
PMID: 40021272 PMC: 11905164. DOI: 10.1016/j.jacadv.2024.101528.
RIP kinases and necroptosis in aging and aging-related diseases.
Yang Y, Li X, Zhang T, Xu D Life Med. 2025; 1(1):2-20.
PMID: 39872161 PMC: 11749793. DOI: 10.1093/lifemedi/lnac003.
Programmed cardiomyocyte death in myocardial infarction.
Wu H, Lan Q, He Y, Xue J, Liu H, Zou Y Apoptosis. 2025; .
PMID: 39833636 DOI: 10.1007/s10495-025-02075-3.
Mechanisms of postischemic cardiac death and protection following myocardial injury.
Mastoor Y, Murphy E, Roman B J Clin Invest. 2025; 135(1).
PMID: 39744953 PMC: 11684816. DOI: 10.1172/JCI184134.
Lv X, Liu B, Su X, Tian X, Wang H J Transl Med. 2024; 22(1):681.
PMID: 39061056 PMC: 11282728. DOI: 10.1186/s12967-024-05204-9.